Literature DB >> 32828183

WSO and WHF joint position statement on population-wide prevention strategies.

Michael Brainin1, Karen Sliwa2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32828183      PMCID: PMC7440876          DOI: 10.1016/S0140-6736(20)31752-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
In 2008, Rod Jackson and colleagues proposed that prevention strategies for high-risk cardiovascular disease, based on screening individuals at high risk of cardiovascular disease, would deliver large benefits for the population. Simon Capewell cautioned that these strategies could mislead health professionals and politicians into thinking they can tick the box reading mission accomplished and, with screening completed, cardiovascular disease prevention would be resolved. Both sides of this debate were based on assumptions and therefore did not reach consensus, but the high-risk approach to the prevention of cardiovascular disease has since been widely recommended and implemented. There is reliable evidence from the Inter99 randomised controlled trial, which included 59 616 people aged 30–60 years followed up for 10 years, and a Cochrane meta-analysis of 15 randomised controlled trials, totalling 251 891 adults, that screening individuals in the general population for the risk of cardiovascular disease and risk factors (even with lifestyle counselling, as in the Inter99 trial) has no significant effect on the incidence and mortality of ischaemic heart disease and stroke. At a population level, the age-standardised incidence and mortality of cardiovascular disease (including stroke) were decreasing before the implementation of high-risk prevention strategies, but have shown less decline since 2010 than the decline during the past 25 years. In some countries, such as the UK, the Netherlands, the USA, and New Zealand (specifically the Māori and Pacific people), the incidence and mortality of cardiovascular disease is increasing, particularly in middle-aged individuals. Furthermore, there is a paucity of robust economic evidence that screening for the risk of cardiovascular disease is cost-effective, there is some evidence that screening might exacerbate socioeconomic inequalities, and there are potential hazards in labelling people as being at low risk of disease, giving them false reassurance that they are protected from cardiovascular disease and compromising any motivation to control risk factors. Therefore, when communicating the absolute risk of cardiovascular disease to patients, the World Stroke Organization (WSO) has suggested that categorising people by low, moderate (mild), and high risk of disease (including heat charts) should be abandoned. Because many of the underlying causes of stroke and cardiovascular disease are well established, identifiable, and controllable, according to Geoffrey Rose, there is not a major role for the high-risk strategy in the primary prevention of stroke and cardiovascular disease. Rather this strategy has a complementary role to the more powerful population-wide strategy. Unfortunately, today the priority is given to the high cardiovascular risk strategy, and this reality needs to be changed.10, 11 There is an urgent need to improve the primary prevention of stroke and cardiovascular disease, with priority given to population-wide primary prevention strategies that would also strengthen global health systems and aid economic recovery in the wake of pandemics such as COVID-19. Further references in support of this position statement are listed in the appendix.
  11 in total

1.  Will screening individuals at high risk of cardiovascular events deliver large benefits? No.

Authors:  Simon Capewell
Journal:  BMJ       Date:  2008-08-28

2.  Will screening individuals at high risk of cardiovascular events deliver large benefits? Yes.

Authors:  Rod Jackson; Sue Wells; Anthony Rodgers
Journal:  BMJ       Date:  2008-08-28

3.  Sick individuals and sick populations.

Authors:  G Rose
Journal:  Int J Epidemiol       Date:  1985-03       Impact factor: 7.196

4.  Global prevention of stroke and dementia: the WSO Declaration.

Authors:  Michael Brainin; Valery L Feigin; Bo Norrving; Sheila Cristina Ouriques Martins; Graeme J Hankey; Vladimir Hachinski
Journal:  Lancet Neurol       Date:  2020-06       Impact factor: 44.182

Review 5.  Are cardiovascular disease risk assessment and management programmes cost effective? A systematic review of the evidence.

Authors:  John Tayu Lee; Kenny D Lawson; Yizhou Wan; Azeem Majeed; Stephen Morris; Michael Soljak; Christopher Millett
Journal:  Prev Med       Date:  2017-01-11       Impact factor: 4.018

6.  General health checks in adults for reducing morbidity and mortality from disease.

Authors:  Lasse T Krogsbøll; Karsten Juhl Jørgensen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2019-01-31

Review 7.  What Is the Best Mix of Population-Wide and High-Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention?

Authors:  Valery L Feigin; Michael Brainin; Bo Norrving; Philip B Gorelick; Martin Dichgans; Wenzhi Wang; Jeyaraj Durai Pandian; Sheila Cristina Ouriques Martins; Mayowa O Owolabi; David A Wood; Graeme J Hankey
Journal:  J Am Heart Assoc       Date:  2020-01-25       Impact factor: 5.501

8.  Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study.

Authors:  Helle Wallach-Kildemoes; Finn Diderichsen; Allan Krasnik; Theis Lange; Morten Andersen
Journal:  BMC Public Health       Date:  2012-08-04       Impact factor: 3.295

9.  Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial.

Authors:  Torben Jørgensen; Rikke Kart Jacobsen; Ulla Toft; Mette Aadahl; Charlotte Glümer; Charlotta Pisinger
Journal:  BMJ       Date:  2014-06-09

Review 10.  Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated.

Authors:  Allan D Sniderman; George Thanassoulis; John T Wilkins; Curt D Furberg; Michael Pencina
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

View more
  7 in total

1.  Ambulatory Cardiovascular Monitoring Via a Machine-Learning-Assisted Textile Triboelectric Sensor.

Authors:  Yunsheng Fang; Yongjiu Zou; Jing Xu; Guorui Chen; Yihao Zhou; Weili Deng; Xun Zhao; Mehrdad Roustaei; Tzung K Hsiai; Jun Chen
Journal:  Adv Mater       Date:  2021-08-31       Impact factor: 32.086

2.  Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

Authors: 
Journal:  Lancet Neurol       Date:  2021-09-03       Impact factor: 59.935

3.  PASCAR and WHF Cardiovascular Diseases Scorecard project.

Authors:  Mpiko Ntsekhe; Jean M Fourie; Wihan Scholtz; Oana Scarlatescu; George Nel; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2021 Jan-Feb       Impact factor: 1.167

4.  The state of stroke services across the globe: Report of World Stroke Organization-World Health Organization surveys.

Authors:  Mayowa O Owolabi; Amanda G Thrift; Sheila Martins; Walter Johnson; Jeyaraj Pandian; Foad Abd-Allah; Cherian Varghese; Ajay Mahal; Joseph Yaria; Hoang T Phan; Gregory Roth; Seana L Gall; Richard Beare; Thanh G Phan; Robert Mikulik; Bo Norrving; Valery L Feigin
Journal:  Int J Stroke       Date:  2021-05-27       Impact factor: 6.948

Review 5.  Primary stroke prevention worldwide: translating evidence into action.

Authors:  Mayowa O Owolabi; Amanda G Thrift; Ajay Mahal; Marie Ishida; Sheila Martins; Walter D Johnson; Jeyaraj Pandian; Foad Abd-Allah; Joseph Yaria; Hoang T Phan; Greg Roth; Seana L Gall; Richard Beare; Thanh G Phan; Robert Mikulik; Rufus O Akinyemi; Bo Norrving; Michael Brainin; Valery L Feigin
Journal:  Lancet Public Health       Date:  2021-10-29

6.  The World Stroke Academy: A World Stroke Organization global pathway to improve knowledge in stroke care.

Authors:  Gustavo Saposnik; Laura Ceci Galanos; Rodrigo Guerrero; Florencia Casagrande; Emili Adhamidhis; Meah Ming Yang Gao; Maria Fredin Grupper; Anita Arsovska
Journal:  Int J Stroke       Date:  2022-03-10       Impact factor: 6.948

7.  Cross-cultural validation of the stroke riskometer using generalizability theory.

Authors:  Oleg Medvedev; Quoc Cuong Truong; Alexander Merkin; Robert Borotkanics; Rita Krishnamurthi; Valery Feigin
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.